par Smyth, J F;Aamdal, S;Awada, Ahmad
;Dittrich, C;Caponigro, F;Schöffski, P;Gore, Martin;Lesimple, Thierry;Djurasinovic, N;Baron, Benoît;Ravic, M;Fumoleau, Pierre;Punt, Cornelis;EORTC New Drug Development and Melanoma Groups,
Référence Annals of oncology, 16, 1, page (158-161)
Publication Publié, 2005-01

Référence Annals of oncology, 16, 1, page (158-161)
Publication Publié, 2005-01
Article révisé par les pairs
Titre: |
|
Auteur: | Smyth, J F; Aamdal, S; Awada, Ahmad; Dittrich, C; Caponigro, F; Schöffski, P; Gore, Martin; Lesimple, Thierry; Djurasinovic, N; Baron, Benoît; Ravic, M; Fumoleau, Pierre; Punt, Cornelis; EORTC New Drug Development and Melanoma Groups, |
Informations sur la publication: | Annals of oncology, 16, 1, page (158-161) |
Statut de publication: | Publié, 2005-01 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Adult |
Aged | |
Disease Progression | |
Female | |
Humans | |
Infusions, Intravenous | |
Male | |
Melanoma -- drug therapy | |
Melanoma -- pathology | |
Middle Aged | |
Skin Neoplasms -- drug therapy | |
Skin Neoplasms -- pathology | |
Sulfonamides -- administration & dosage | |
Sulfonamides -- adverse effects | |
Sulfonamides -- therapeutic use | |
Treatment Outcome | |
Note générale: | Clinical Trial |
Clinical Trial, Phase II | |
Journal Article | |
Multicenter Study | |
Langue: | Anglais |
Identificateurs: | urn:issn:0923-7534 |
info:doi/10.1093/annonc/mdi016 | |
info:pii/16/1/158 | |
info:scp/19944427395 | |
info:pmid/15598954 |